Empagliflozin: A New Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Drugs in Context - United Kingdom
doi 10.7573/dic.212262
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BioExcel

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy